Risk of infection during treatment with tumor necrosis factor-α inhibitors;Risiko von infektionen unter einer behandlung mit tumornekrosefaktor- α-inhibitoren

Zeitschrift fur Rheumatologie

Volumn 65, Issue 1, 2006, Pages 24-31

  Gaemperli, A ^a   Hauser, T ^a   Speck, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adalimumab; Etanercept; Infectious diseases; Inflammatory rheumatic diseases; Infliximab; Tumor necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; CANDIDIASIS; CHRONIC DISEASE; COCCIDIOIDOMYCOSIS; DRUG EFFICACY; GRANULOMA; HISTOPLASMOSIS; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; INFECTION RISK; INFLAMMATORY CELL; LISTERIOSIS; RHEUMATIC DISEASE; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644898122     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0018-z     Document Type: Article

References (44)

1. Algood HM, Lin PL, Flynn JL (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 [Suppl 3]:S189-S193
2. Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331-335
3. Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 4:162-170
4. Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 [Suppl 2]:1118-1124
5. Carswell EA, Old LJ, Kassel RL et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666-3670
6. Chan AT, Cleeve V, Daymond TJ (2002) Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78:47-48
7. Crowe PD, van Arsdale TL, Walter BN et al. (1994) A lymphotoxin-beta- specific receptor. Science 264:707-710
8. Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291-302
9. Deepe GS Jr (2005) Modulation of infection with histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 41 [Suppl 3]:S204-S207
10. Deepe GS Jr, Smelt S, Louie JS (2005) Tumor necrosis factor inhibition and opportunistic infections. Clin Infect Dis 41 [Suppl 3]:S187-S188
11. De Rosa FG, Shaz D, Campagna AC et al. (2003) Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 24:477-482
12. Dimakou K, Papaioannides D, Latsi P et al. (2004) Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int J Clin Pract 58:1052-1055
13. Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41 [Suppl 3]:S199-5203
14. Elkayam O, Caspi D, Reitblatt T et al. (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283-288
15. Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013-3022
16. Filler SG, Yeaman MR, Sheppard DC (2005) Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 41 [Suppl 3]:S208-S212
17. Flynn JL, Chan J (2001) Tuberculosis: latency and reactivation. Infect Immun 69:4195-4201
18. Geborek P, Crnkic M, Petersson IF, Saxne T (2002) Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 61:793-798
19. Giles JT, Bathon JM (2004) Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19:320-334
20. Gomez-Reino JJ, Carmona L, Valverde VR et al. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-2127
21. Gordin F, Chaisson RE, Matts JP et al. (2000) 2000. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283:1445-1450
22. Hage CA, Wood KL, Winer-Muram HT et al. (2003) Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124:2395-2397
23. Hayder H, Blanden RV, Korner H et al. (1999) Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin. J Immunol 163:1516-1520
24. Hyrich KL, Silman AJ, Watson KD, Symmons DP (2004) Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538-1543
25. Kallinowski B, Haseroth K, Marinos G et al. (1998) Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269-277
26. Karrer W (2000) Tuberculosis in Switzerland - a millenium problem? Schweiz Med Wochenschr 130:282-290
27. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
28. Keystone EC (2005) Safety of biologic therapies - an update. J Rheumatol Suppl 74:8-12
29. Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617-621
30. Lee JH, Slifman NR, Gershon SK et al. (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565-2570
31. Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
32. Nash PT, Florin TH (2005) Tumour necrosis factor inhibitors. Med J Aust 183:205-208
33. Parke FA, Reveille JD (2004) Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51:800-804
34. Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17-21
35. Roach DR, Bean AG, Demangel C et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168:4620-4627
36. Roberts L, McColl GJ (2004) Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 34:687-693
37. Ruby J, Bluethmann H, Peschon JJ (1997) Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 186:1591-1596
38. Schluter D, Deckert M (2000) The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect 2:1285-1292
39. Seddik M, Melliez H, Seguy D et al. (2005) Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 11:618-620
40. Stenger S (2005) Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 64 [Suppl 4]:iv24-iv28
41. Taylor JC, Orkin R, Lanham J (2003) Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford) 42:901-902
42. Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A (2005) Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 99:648-652
43. Wallis RS, Broder M, Wong J et al. (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 [Suppl 3]:S194-S198
44. Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787-819